PNV Media Thread, page-1713

Interesting article from AFR, regarding Triad Life Sciences, which like PNV are in the wound care space. They are intending to list on ASX in December.

"Triad Life Sciences prices $540m float, ready to front investors Emerging biotech company Triad Life Sciences has donned the hard hat and is pushing ahead with plans to raise $40 million for its in initial public offering via Canaccord Genuity.
The wound treatment business has booked meetings with potential investors this week, according to an email sent to fund managers, aiming to list on the ASX with a $540 million market capitalisation before Christmas.
The Memphis-headquartered company has made a product that helps serious wounds heal called InnovaMatrix using placental material, combined with a technology platform.
It has US Food and Drug Administration clearance and its brokers say its wound management product has better economics - costing less and having higher margins - than competing products.
The placental wound care market in the US is estimated to be worth $US1.4 billion, according to Triad.
The business is led by CEO Russ Olsen, who has held senior positions at biotech giants Bristol-Myers Squibb and Smith & Nephew.Based on September quarter sales, Triad has a $36 million annualised revenue run rate.
Revenue has been growing at more than 60 per cent quarter on quarter.
It’s expected to be compared to other ASX-listed regenerative medicine companies Aroa Biosurgery and PolyNovo.Aroa is tracking toward $NZ33 million of sales revenue in 2022, while PolyNovo reported $29.3 million in revenue for the 2021 financial year.
Having been heavily sold off since January, PolyNovo is trading at $1.51 per share and has a $998.7 million market capitalisation (down 61.6 per cent this year). At this price, it trades at 13 times trailing revenue, while Aroa Biosurgery is 11.5 times forecast revenue. "